Genflow Biosciences signs CDAs for dog longevity with animal health groups

Genflow Biosciences PLC CEO Dr Eric Leire joined Proactive's Stephen Gunnion with news that the company has signed confidential disclosure agreements (CDAs) with two major animal health companies. Leire explained that these discussions are significant for shareholders as they broaden the company’s market potential, provide possible early cash inflows to reduce capital needs, and validate its scientific platform. “Our core science is focused on tackling ageing and muscle loss. The same approach we use for humans has real potential for companion animals,” Leire said. He noted that the global pet market is expanding, and Genflow’s work in this area could deliver solutions to extend lifespan and improve the quality of life for ageing dogs. He also highlighted that early safety data from the company’s first dog trials have been positive. The administration of the treatment was straightforward, with no signs of discomfort or behavioural change in the animals. Leire said this suggests the product could translate into a commercially viable therapy. The next key milestone will be efficacy data from the dog trials, expected within five months. Leire expressed confidence, citing strong results previously observed in mice studies. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to give the video a like, subscribe to the channel, and enable notifications for future content. #GenflowBiosciences #Biotech #Longevity #AnimalHealth #PetWellness #DrugDevelopment #ClinicalTrials #AgingResearch #LifeSciences #InvestorNews